Taiwan Exosome BioTherapeutics Co., Ltd.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
Orthopedic/Dental Bone Graft and Filling Materials, Periodontal Regeneration Membrane
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2022
Unified Business No.
89155391
Status
Active
Number of Employees
2
Total Paid-in
Capital
3,000,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taiwan Exosome BioTherapeutics Co., Ltd. is dedicated to developing and applying cells, their derivatives, and related biomedical materials, such as orthopedic/dental filling materials and periodontal regenerative membranes, to oral tissue reconstruction. Using the twenty years of cell testing experience of its founder, Dr. Wen-Chun Kuo, as a bridge, the company combines academic research with industrial development to develop new medical biomedical composite materials.
In July 2022, it was officially licensed to Taiwan Exosome BioTherapeutics Co., Ltd. for product development and the optimization of biomedical material manufacturing processes, moving forward toward applying for Class II medical devices.
(The content above was translated by AI.)
In July 2022, it was officially licensed to Taiwan Exosome BioTherapeutics Co., Ltd. for product development and the optimization of biomedical material manufacturing processes, moving forward toward applying for Class II medical devices.
(The content above was translated by AI.)
